ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
Equity
Direct
Sector - Healthcare
About the Fund
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is an equity fund. This fund was started on 12 July, 2018. The fund is managed by Dharmesh Kakkad. The fund could potentially beat inflation in the long-run.
Key Parameters
- ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth has ₹4125 Cr worth of assets under management (AUM) as on Jun 2024 and is more than category average.
- The fund has an expense ratio 1.1.
Returns
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth has given a CAGR return of 24.07% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 52.32%, 18.75% and 30.44% respectively.
Holdings
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Financial Services, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Dr Reddy's Laboratories Ltd, Cipla Ltd, Aurobindo Pharma Ltd, Lupin Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 15%For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefitDividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.
Investment objective of ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
To generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. However there can be no assurance or guarantee that the investment objectives of the scheme would be achieved.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 100.00. ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth has no lock in period.
Fund Performance
2425 people have invested ₹ 1.7Cr in ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth in the last three months
INDmoney Rank
Powered by IND quant engine
IND ranking is not available for this fund.
5Y returns in the top 25% of the category
3Y returns in the top 25% of the category
Larger AUM within category
No bad points found for this fund.
Fund Overview
| Expense ratio | 1.07% |
Benchmark | S&P BSE Healthcare PR |
| AUM | ₹4125 Cr |
| Inception Date | 12 July, 2018 |
| Min Lumpsum/SIP | ₹5000/₹100 |
Exit Load | 1% |
| Lock In | No Lock-in |
TurnOver | 49.46% |
| Risk |   Very High Risk |
Fund Distributionas on (30-Jun-24)
Large cap
44.5%
Mid cap
27.2%
Small cap
26.5%
Sector Allocation
Health
92.1%
Financial Services
4%
Basic Materials
3.9%
All changes are between Apr'24 and Jun'24
as on (30-Jun-24)
See all
Returns for the month of Jun
Top Growth Drivers | 1M Return |
|---|---|
 Dr Reddys Laboratories Ltd | 13.4% |
 Shilpa Medicare Ltd | 7.9% |
 Sun Pharmaceuticals Industries Ltd | 7.2% |
Dharmesh Kakkad
Fund Manager of ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth, since 2 May 2020
Top funds managed
Mutual Fund Insights
Over the last 1 month, this fund has increased expense ratio by 3.9% moving from 1.03 to 1.07.
In the last 3 years, this fund has outperformed all funds in its category.
In the last 1 year, Quant Healthcare Fund Direct Growth has given 60.96% return, outperforming this fund by 8.63%.
In the last 5 years, DSP Healthcare Fund Direct Growth has given 31.51% return, outperforming this fund by 1.07% per annum.
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.07% which is lower than the category average expense ratio of 1.42%.
Over the last 6 months, this fund has experienced a 22.7% growth in AUM moving from 3.36K Cr to 4.12K Cr.
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 24.07% since inception which is more than its category average return of 23.79%
Fund Allocations
This fund has an allocation of 98.25% in Equity, 0% in Debt and 1.75% in Cash related instruments
AUM size ₹4125 Cr
This fund has AUM of ₹4125 Cr which is more than its category average of ₹ 1743 Cr
Expense Ratio 1.07%
This fund has an expense ratio of 1.07% which is less than its category average expense ratio of 1.44%
Frequently Asked Questions
The current NAV of ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is ₹37.03 as on 25-Jul-2024.
Existing (Absolute + CAGR) as on 25-Jul-2024.
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 7.46% | 7.46% |
6 Month Returns | 20.93% | 20.93% |
1 Year Returns | 52.32% | 52.32% |
3 Years Returns | 67.46% | 18.75% |
5 Years Returns | 277.6% | 30.44% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
1.07% as on June 2024
₹4125 Cr as on June 2024
Sun Pharmaceuticals Industries Ltd(14.75%), Dr Reddy's Laboratories Ltd(7.79%), Cipla Ltd(7.16%), Aurobindo Pharma Ltd(6.51%), Lupin Ltd(6.01%) as on June 2024
Health(90.52%), Financial Services(3.89%), Basic Materials(3.84%) as on June 2024
The alpha ratio for the ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | 7.05 | 3.86 | 4.21 |
As on June 2024
The alpha for ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | 0.86 | 0.88 | 0.94 |
As on June 2024
The Beta for ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | 2.58 | 0.83 | 1.17 |
As on June 2024
The sharpe ratio for ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | 13.36 | 14.03 | 18.74 |
As on June 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.52 as on June 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.9 as on June 2024. It tells the consistency of the fund in generating superior risk-adjusted performance
Dharmesh Kakkad is the fund manager of ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
The Exit load of ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is 1%